Home › Lymphoma › North Carolina
Lymphoma clinical trials in North Carolina
22 studies for Lymphoma are looking for participants at sites in North Carolina.
Cities in North Carolina
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Levine Children's Hospital- Pediatric Neuro-Oncology, Charlotte
RecruitingPhase 1/2
Up to age 25 · All sexes · Updated Sep 25, 2026 · NCT04094610CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill
- Wake Forest Baptist Medical Center, Winston-Salem
RecruitingPhase 2
Ages 18 to 99 · All sexes · Updated Sep 24, 2026 · NCT04083495A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Duke University, Durham
- Novant Health Cancer Institute, Winston-Salem
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07221500CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Duke University Medical Center, Durham
RecruitingPhase 1/2
12 Months – 21 Years · All sexes · Updated Sep 11, 2026 · NCT04870944Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- UNC School of Medicine, Division of Hematology, Chapel Hill
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 3, 2026 · NCT04588922Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Atrium Health Wake Forest Baptist, Winston-Salem
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT05826535DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill
Recruiting
Ages 60 and older · All sexes · Updated Aug 14, 2026 · NCT06296368Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Aug 6, 2026 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Duke Cancer Institute, Durham
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Duke University Medical Center - Division of Hematologic Malignancies, Durham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT04792489A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Duke University Medical Center, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT05131022Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
- North Carolina Basnight Cancer Hospital, Chapel Hill
Recruiting
Ages 18 and older · All sexes · Updated Jul 1, 2026 · NCT06860880Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- and 4 more
RecruitingObservational study
Ages 65 and older · All sexes · Updated Jun 29, 2026 · NCT01137825Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Mission Hospital, Asheville
- Wake Forest University Health Sciences, Winston-Salem
RecruitingObservational study
All ages · All sexes · Updated May 18, 2026 · NCT01790152CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Duke University Medical Center, Duke Cancer Center, Durham
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 16, 2026 · NCT03328078A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of North Carolina, Chapel Hill
RecruitingPhase 2
Ages 18 to 66 · All sexes · Updated Mar 17, 2026 · NCT06859424A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
- Carolina BioOncology, Huntersville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 4, 2026 · NCT05892718Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
- Duke Cancer Institute, Durham
Recruiting
Ages 18 to 39 · All sexes · Updated Jan 28, 2026 · NCT06371768Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jan 20, 2026 · NCT04223765Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
- Novant Health Breast Surgery - Greensboro, Greensboro
- Novant Health Cancer Institute - Kernersville, Kernersville
- Novant Health Cancer Institute - Mount Airy, Mount Airy
- and 3 more
RecruitingPhase 3Healthy volunteers welcome
Ages 18 and older · All sexes · Updated Jan 13, 2026 · NCT05006482Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 27, 2025 · NCT01137643A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Durham VA Medical Center, Durham, NC, Durham
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Oct 14, 2025 · NCT06520098From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.